000999.SHE China Resources Sanjiu Medical & Pharmaceutical Co Ltd
- Market cap
- CNY 42.1B
- P/E
- 13.0x
- P/B
- 1.86x
- ROE
- 12.7%
- Dividend yield
- 2.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000999.SHE undervalued?
Graham number000999.SHE trades 3.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Resources Sanjiu Medical & Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for China Resources Sanjiu Medical & Pharmaceutical Co Ltd yet.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, flu, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, …
Full company profileChina Resources Sanjiu Medical & Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.98B | 11.1B | 13.4B | 14.8B | 13.6B | 15.5B | 18.1B | 24.7B | 27.6B | 31.6B | 28.5B |
| Gross Profit | 5.60B | 7.22B | 9.26B | 9.89B | 8.49B | 8.98B | 9.73B | 13.1B | 14.2B | 17.0B | 16.0B |
| Operating Income | 1.28B | 1.51B | 1.70B | 2.51B | 2.07B | 2.47B | 2.95B | 3.75B | 4.48B | 4.85B | 4.88B |
| EBITDA | 1.77B | 1.87B | 2.10B | 2.90B | 2.46B | 2.89B | 3.45B | 4.53B | 5.32B | 5.50B | 4.37B |
| Net Income | 1.20B | 1.30B | 1.43B | 2.10B | 1.60B | 2.06B | 2.45B | 2.85B | 3.37B | 3.42B | 2.88B |
| EPS | 0.72 | 0.79 | 0.86 | 1.27 | 0.96 | 1.24 | 1.47 | 1.72 | 2.02 | 2.06 | 1.73 |
| Balance Sheet | |||||||||||
| Total Assets | 13.6B | 16.2B | 18.0B | 21.4B | 22.2B | 24.5B | 27.1B | 40.1B | 40.1B | 58.8B | 55.4B |
| Total Liabilities | 4.83B | 6.07B | 6.86B | 8.32B | 8.10B | 8.77B | 9.59B | 15.9B | 14.8B | 20.0B | 16.7B |
| Shareholders' Equity | 8.62B | 9.84B | 10.8B | 12.8B | 13.7B | 15.3B | 17.0B | 19.0B | 19.9B | 22.2B | 22.6B |
| Cash & Short-term Investments | 1.31B | 1.71B | 2.48B | 3.09B | 4.02B | 4.28B | 3.15B | 8.23B | 6.69B | 9.56B | 3.19B |
| Total Debt | 520M | 30.2M | 45.2M | 40.2M | 173M | 187M | 325M | 2.81B | 1.13B | 6.42B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.39B | 1.60B | 1.91B | 1.97B | 2.22B | 1.88B | 3.01B | 4.19B | 4.40B | 5.51B | - |
| Capital Expenditure | 354M | 375M | 600M | 536M | 622M | 871M | 952M | 857M | 790M | 1.27B | 1.14B |
| Free Cash Flow | 1.04B | 1.19B | 1.31B | 1.44B | 1.60B | 1.01B | 2.05B | 3.33B | 3.61B | 4.34B | 1.93B |
| Ratios | |||||||||||
| ROE | 13.9% | 13.2% | 13.2% | 16.4% | 11.6% | 13.4% | 14.4% | 15.0% | 16.9% | 15.4% | 12.7% |
| ROA | 8.8% | 8.0% | 7.9% | 9.8% | 7.2% | 8.4% | 9.0% | 7.1% | 8.4% | 5.8% | 5.2% |
| Net Profit Margin | 13.3% | 11.7% | 10.7% | 14.2% | 11.7% | 13.2% | 13.5% | 11.5% | 12.2% | 10.8% | 10.1% |
| Debt to Equity | 0.06x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.02x | 0.15x | 0.06x | 0.29x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.98%
- Forward dividend
- 1.01 CNY
- Payout ratio
- 36.7%
- Ex-dividend date
- Oct 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.26B | 0.76 | 36.7% |
| 2024 | CNY 2.83B | 1.70 | 84.2% |
| 2023 | CNY 1.06B | 0.63 | 37.0% |
| 2022 | CNY 842M | 0.50 | 34.4% |
| 2021 | CNY 496M | 0.30 | 24.1% |
| 2020 | CNY 421M | 0.25 | 26.3% |
| 2019 | CNY 382M | 0.23 | 18.2% |
| 2018 | CNY 491M | 0.30 | 34.3% |
| 2017 | CNY 182M | 0.11 | 14.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 6, 2025.
Who owns China Resources Sanjiu Medical & Pharmaceutical Co Ltd
- Insiders 64.85%
- Institutions 5.70%
- Public & others 29.45%
- Shares outstanding 1.66B
- Free float 563M
China Resources Sanjiu Medical & Pharmaceutical Co Ltd company profile
- Company name
- China Resources Sanjiu Medical & Pharmaceutical Co Ltd
- Ticker
- 000999.SHE
- ISIN
- CNE0000011K8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 11, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 30,304
- Fiscal year end
- December
- Address
- Guanlan High-tech Park, Shenzhen, China, 518110
- Phone
- 86 755 8336 0999
- Website
- 999.com.cn
About China Resources Sanjiu Medical & Pharmaceutical Co Ltd
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers health consumer products (CHC), including cold, flu, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, anti-infection, and other treatment areas; Chinese medicine health products; and vitamins, minerals, protein powder, collagen, probiotics, health foods, and formula granules. It also provides related health services. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. was incorporated in 1999 and is headquartered in Shenzhen, China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources Pharmaceutical Group Limited.
China Resources Sanjiu Medical & Pharmaceutical Co Ltd management
6- Mr. Wen Duo WuPresident & Director · born 1974
- Mr. Jian XingCFO & Secretary of the Board · born 1978
- Mr. Yi MaiVice President · born 1967
- Mr. Liang WangVice President · born 1979
- Mr. Ke WangVice President · born 1974
- Mr. Yu XiangVice President · born 1981